Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions

Drug Metab Pharmacokinet. 2020 Feb;35(1):18-29. doi: 10.1016/j.dmpk.2019.11.007. Epub 2019 Dec 20.

Abstract

Drug-drug interactions (DDIs) involving drug-metabolizing enzymes and membrane transporters can lead to alteration in substrate drug (victim) exposure, and can influence the pharmacological and toxicological effects. In order to predict DDI potential, it is important to quantitatively characterize the major enzyme(s) and/or transporter(s) involved in the clearance of drugs, in terms of fraction metabolized (fm) and fraction transported (ft). In this review, we discuss a strategy using Extended Clearance Classification System (ECCS) to identify the clearance mechanism(s) early in drug discovery, and subsequently rational staging of in vitro characterization to determine fm and ft. In addition, the examples of complex DDIs due to involvement of transporter-enzyme interplay in the hepatic clearance are discussed.

Keywords: Complex DDI; Drug-drug interaction (DDI); Extended clearance classification system (ECCS); Fraction metabolized (f(m)); Fraction transported (f(t)); Transporter-enzyme interplay.

Publication types

  • Review

MeSH terms

  • Drug Interactions
  • Enzymes / metabolism*
  • Humans
  • Liver / metabolism*
  • Membrane Transport Proteins / metabolism*
  • Metabolic Clearance Rate*
  • Pharmaceutical Preparations / metabolism*

Substances

  • Enzymes
  • Membrane Transport Proteins
  • Pharmaceutical Preparations